Summary
Introduction
Transient hypogammaglobulinaemia of infancy (THI) is a heterogeneous and transient immunoglobulin production defect often extending into early childhood, which is defined as the depression of IgG serum levels to more than 2SD below the mean age-specific reference value in a child who otherwise lacks any known congenital immunodeficiency. 1, 2 The prevalence of primary immunodeficiencies for Turkish patients is 30.5/100,000 (18.8/100,000 for Ege University records) in the ESID (European Society for Immune Deficiencies) database; two thirds of them are humoral immunodeficiencies. 3 THI is the most common disorder with a prevalence of 7.01/100,000 in registered patients. 3 Maturation delay in the normal production of immunoglobulins resolves by 30-40 months of life 1, 2 and rarely extends up to 5 years. 4 In the blood samples of these patients, initial serum IgG levels are lower than two standard deviations below the mean for age-specific reference values. Then, they begin to increase and are followed by normal values. The diagnosis of THI can be made retrospectively. 5, 6 Most of the patients frequently have mild infections and/or are sometimes asymptomatic. About 20% of THI patients may have very severe infections and need hospitalisation because of these infections. 7 In addition, these infections damage the quality of life and prevent attendance at day-care centres. The Primary Immunodeficiency Committee classifies THI among primary humoral immunodeficiency and suggests that severely symptomatic THI children should be treated with intravenous immunoglobulin (IVIg) only after the failure of large spectrum antibiotic prophylaxis. 8, 9 In paediatric immunology clinics, IVIg is preferred in about 10-20% of THI patients to stop the vicious circle of recurrent infections. 1, 9 However, it is not still clear why some of the patients are severely symptomatic and others are not. It has been suggested that there might be additional immunologic or environmental factors or some other co-morbidities for those THI patients who need IVIg to prevent infections.
Fcγ receptors-expressed on haematopoietic cells, including macrophages, dendritic cells, and neutrophils, occur in different subtypes, some of which are activating and others are inhibitory. Fcγ receptors provide a link between cells of the innate and adaptive immune systems. 10 Several studies have shown that IVIg may influence the effect of Fc receptor-mediated activity of immune relevant cells by interacting with Fc regions. 10 It is generally thought that IVIg acts to block activating receptors, induce inhibitory factors and cause a downregulation of the damaging activity of macrophages. 10 On the other hand, it has been reported that the FcγRIIa gene polymorphism (R131R) may increase the risk and susceptibility for recurrent infectious diseases in children. 11 It might be speculated that some THI patients may have some FcγR gene polymorphisms increasing the severity of illness. Furthermore, clinical response and the success of IVIg therapy in THI patients may have an association with these polymorphisms.
The most abundant immunoglobulin, IgG, mediates key effector functions through interaction with Fcγ receptors (FcγRI, FcγRII, FcγRIII) encoded by distinct genes, and differ in their distribution on different cell types, strength and capacity. 12, 13 Polymorphisms in the human FcγR genes IIa, IIIa and IIIb further enhance the heterogeneity of these molecules. 13 In this study, we aimed to identify the Fcγ receptor polymorphisms in THI patients with very severe infections who needed hospitalisation (treated with IVIg) and in THI patients who were asymptomatic or had mild infections (treated with antibiotics or received no medication) in order to understand whether there is an association between the heterogeneous clinical picture of THI patients and FcγR genes polymorphisms.
Methods

Study design and patient characteristics
The following criteria were used to diagnose THI patients in Ege University Faculty of Medicine, Department of Paediatric Immunology, Izmir, Turkey: 1-At admission, IgG serum levels below up two standard deviations (SD) of age-related normal values; 2-circulating B cells >2%; and 3-the exclusion of known causes of hypogammaglobulinaemia such as drugs, genetic disorders, chromosomal abnormalities, infectious diseases, neoplasia, systemic disorders and prematurity. Forty-three patients whose IgG reached age-related normal levels during follow-up were included in the study. In these patients, 18 of them received IVIg (IVIg group) and 25 patients received prophylactic antibiotics or did not receive any medication (nonIVIg group) before normalisation of their immunoglobulin levels.
THI patients with the following criteria had received IVIg therapy: 1-patients who had six times or more upper respiratory infections and/or otitis media, or two or more sinusitis, or one or more pneumonia in one year; 2-patients who used antibiotics more than six times a year; 3-patients who needed intramuscular or intravenous injection for the recovery of infections; and 4-patients who had severe infections such as meningitis or sepsis. Patients fulfilling these criteria had received 400-500 mg/kg IVIg with 4 week intervals and were all monitored for IgG-M-A levels just before IVIg replacement. Ethics Committee approval and informed written consent for participation was obtained in all cases.
Demographic data such as name, gender, date of birth, age at onset of symptoms, age at admission, age at diagnosis, family history, follow-up and IVIg therapy duration, as well as clinical data including frequency of infections, were also recorded.
Methods
The following laboratory methods were used for the evaluation of THI patients:
Whole blood count, leucocyte counts, absolute neutrophil and lymphocyte counts were analysed with a haemocounter, Cell-Dyn 3700, Abbott Diagnostics, USA. Serum immunoglobulins (IgG, IgM, IgA) were analysed quantitatively by Dade Behring BNII nephelometer, Siemens, Germany. Percentages and absolute counts of lymphocyte subsets (T, B, T helper, T cytotoxic, natural killer and active T cell) were investigated by flow cytometry, FACSCalibur, Becton Dickinson, USA. All cell subpopulations were acquired using Cell Quest-Pro software (BD Biosciences). Antibody responses to tetanus and Haemophilus influenza were analysed by commercial ELISA kits.
Fcγ receptor genotyping analyses
All patients were evaluated for Fcγ receptors polymorphisms as follows: H/H-131, H/R-131 and R/R-131 for FcγIIa; V/V-158, V/F-158 and F/F-158 for FcγRIIIa; NA1/NA1, NA1/NA2 and NA2/NA2 for FcγRIIIb.
DNA purification
Blood Mini Kits (Qiagen GmbH, Hilden, Germany) were used according to the manufacturer's instructions.
FcγIIa genotyping
FcγIIa genotyping was performed by using the method defined by Flesch et al. (14) . A 25 µL PCR mixture containing 2.5 µL of 10x PCR buffer (Applied Biosystems, Foster City, CA, USA), 2 mM MgCl 2 , 200 µM of each dNTP (Promega, Madison, USA) and 0.5 U AmpliTag DNA Polymerase (Applied Biosystems) were used. In addition, 0.5 µM of H131-specific sense primer (5'-ATCC-CAGAAATTCTCCCA-3') from the extracellular domain or 0.5 µM R131-specific sense primer (5'-ATCCCAGAAATTCTCCCG-3') was used. 
FcγIIIa genotyping was performed using the method of Van den Berg et al. 15 In this amplification refractory mutation system-PCR, the allele specific primers (KIM-G(V): 5'TCTCTGAAGACACATTT TACTCCCTAC-3' and KIM-1 (F): 5'-TCTCTGA AGACACATTTCTACTCCCTAA-3') amplified a 160-bp fragment with their anti-sense downstream primer A103 (5'-ATATTTACAGAATGGCACA GG-3'). The internal control primers were Ctrl-1 and Ctrl-2, amplifying a 270-bp product. Again, two PCR procedures were required to genotype a subject.
Reactions were performed with 175 ng of genomic DNA in a 25 µL reaction volume, containing 2.5 µL PCR Gold buffer, 62.5 nmol 
FcγIIIb genotyping
FcγIIIb gene genotyping was performed using the method of Bux et al. 16 The NA1-specific primer (5'-CAGTGGTTTCACAATGTGAA-3') gave a 141-bp fragment, and the NA2-specific primer (5'-CAATGGTACAGCGTGCTT-3') amplified a 219-bp fragment. The reverse primer (5'-ATGG ACTTCTACCTGCAC-3') did not differentiate between the two allotypes. Because there was a substantial difference in length between the NA1-specific and NA2-specific reaction products, both alleles could be detected in the same reaction. The 25 µL reaction mixture used contained 100 ng of genomic DNA, 3. To validate the accuracy and reproducibility of the results obtained using the techniques described above, we randomly ran 20% of samples from both groups for each FcγIIa, FcγIIIa and FcγIIIb genotype using a direct DNA sequencing technique with the ABI PRISM 310 Genetic Analyser System (Applied Biosystems).
Statistical analysis
All clinical and laboratory data between the IVIg and non-IVIg groups were compared with each other. Statistical analyses were performed using SPSS Windows Version 17.0, SPSS Inc., Chicago, IL and the Epi-info 3.3.2 program. A two-sided p value less than 0.05 was considered to indicate statistical significance. Odds ratios (OR) with 95% confidence intervals (95% CI) were calculated and deviation from the Hardy Weinberg expectancy was examined with the Chi-square test.
Results
Clinical and immunological data of 43 THI patients (n = 15, 35% female and n: 28, 65% male) between the ages of 12 and 112 months (mean 47.7+22.1) were evaluated. A total of 42% patients (n = 18) received IVIg treatment and twenty-five patients (58%) who were not treated with IVIg served as disease control group. Demographical and clinical data of two groups were listed in Table 1 .
The onset of symptoms were earlier in IVIg group (p = 0.085) and there was a statistically significant difference for the median age at first admission to our clinic (10 and 18 months in IVIg and non-IVIg group, respectively) (p < 0.001). When receiving regular IVIg therapy, there was no statistically significant difference in terms of frequency of infections between two groups (p = 0.773), although infections were much more frequent and severe before these patients joined the IVIg group.
Initial immunoglobulin concentrations were significantly lower in the IVIg group than the nonIVIg group for IgG (p < 0.001) and IgA (p = 0.013) showing the severity of immune deficiency in those patients who were recruited into the IVIg therapy group. Lymphocyte subsets did not show any statistically significant difference between the two groups. Specific antibody response against tetanus (anti-tetanus IgG) and Haemophilus influenzae type B (anti-Hib IgG) were found to be very low and inadequate in the IVIg group ( Table 2 .
In the IVIg group, patients presented a genotype distribution as follows: 50% H131H homozygote (n = 9), 38.9% H131R heterozygote (n = 7), and 11.1% R131R homozygote genotype (n = 2) for FcγRIIa; 38.9% V158V homozygote (n = 7), 50% V158F heterozygote (n = 9), and 11.1% F158F homozygote (n = 2) genotype for FcγRIIIa; and 33.3% NA1 (n = 6), 44.4% NA1/NA2 heterozygote (n = 8) and 22.2% NA2 (n = 4) genotype for FcγRIIIb.
In the non-IVIg group, patients presented 28% H131H homozygote (n = 7), 68% H131R heterozygote (n = 17), and 4% R131R homozygote genotype (n = 1) for FcγRIIa; 16% V158V homozygote (n = 4), 72% V158F heterozygote (n: 18), and 12% F158F homozygote (n = 3) genotype for FcγRIIIa; and 32% NA1 (n = 8), 52% NA1/NA2 heterozygote (n = 13) and 16% NA2 (n = 4) genotype distribution for FcγRIIIb.
Genotypic distributions between two groups did not deviate significantly from the Hardy-Weinberg equilibrium expectations (p > 0.05) ( Table 2) . Odds ratios for "disease risk estimate" did not show dominance for any genotype in either group.
When we compared lymphocyte subsets according to genotype distribution, in the IVIg group, the initial CD19% was significantly lower in patients with the R131R genotype (p = 0.026). Genotypes H131H (p = 0.009) and H131R (p = 0.001) were more commonly present in male patients than in females and consanguinity was seen in patients with V158F genotype (p = 0.023), in the IVIg group.
Allele frequencies for both groups are summarised in Table 3 . Odds ratios that were calculated for the mutated allele in relation to the normal allele did not show any significant difference between two groups (p > 0.05). In other words, none of these alleles had an effect on disease development. The number of infections per year (at admission) for each Fcγ receptor genotype also did not show any significant difference between IVIg and non-IVIg groups (Table 4) .
Discussion
THI is characterised by a maturation delay in the normal production of immunoglobulin and resolves by three to five years old. 1, 10 In the report of Walker et al., 17 the mean age of symptoms of THI patients was 10 months (range 2-24). The beginning of symptoms was earlier in the IVIg group (median 2.75 months) compared to other THI patients who did not receive IVIg (median 6 months). This was a supporting finding showing the severity of infections and the importance of beginning IVIg therapy. Antibiotic prophylaxis or follow-up without medication is often preferred by physicians, but some authors have proposed that a lack of specific antibodies should be used as a decision point when treating THI patients with IVIg. 17, 18 Duse et al. 9 suggested that IVIg should be used in severely symptomatic children in order to stop the vicious circle of recurrent infections. The data obtained from patient records before including them into the study showed that infections were much more frequent and severe in the IVIg patient group (Table  1) . Another important finding was the significantly lower levels of IgG, IgA and anti-tetanus IgG antibody levels in THI patients who were recruited into the IVIg group using only clinical findings.
Fc receptors for IgG form an essential bridge between the humoral branch and the effector cells of the immune system. 19 The two genetically determined structurally different allotypes of human FcγRIIa, the products of the FcγRIIa-R131 and FcγRIIa-H131 alleles, have functionally different reactivities with human IgG2. 19 In humans, FcγRIIa-R131 allotype does so only poorly. 19 Furthermore, binding studies using Ig fusion proteins of FcγRIIa (CD32A) alleles showed that the R allele has significantly lower binding not only to human IgG2, but also to IgG1 and IgG3 subtypes. 20 Fcγ receptor polymorphisms are considered to be heritable risk factors for autoimmune and infectious diseases and support for a relevant role of these polymorphisms has been obtained in previous studies. Results from association studies are sometimes contradictory, possibly due to differences in the inclusion criteria, sample size, ethnicity and definitions of disease severity. The FcγRIIa-R131R genotype was found to be enriched among bacteriaemic pneumonia patients, suggesting that this polymorphism increases host susceptibility to pneumonia. 21 Similar to this study, decreased frequencies of FcγRIIa-H131H genotypes among Dutch children with recurrent upper airway infections by S. pneumonia have been reported. 22 In a previous study, the FcγRIIa-R131R genotype in children with recurrent febrile infections (25%) was significantly higher than that in the healthy controls (4.2%) (p = 0.001).
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In addition, the R131R allele was higher in the study group, whereas H131 was higher in the control group, which suggests that the existence of the R131 allele alone increases the risk of infectious diseases.
The clinical findings of THI patients are very heterogeneous, with some of them presenting recurrent, severe and early beginning infections (IVIg group in this study) and others being asymptomatic or rarely presenting mild infections (non-IVIg group). There might be an additional immunological factor such as Fcγ receptor polymorphisms causing severe and recurrent infections. We searched out the Fcγ receptor polymorphisms in both groups of THI patients. Genotypic distributions between two groups did not deviate significantly from the Hardy-Weinberg equilibrium expectations (p >0.05) and odds ratios for "disease risk estimate" did not show dominance for any genotype in both groups. In addition, different Fcγ receptor genotypes had a similar number of infections in the IVIg and non-IVIg group (Table 4 ). There are no other studies in the literature investigating the Fcγ receptor polymorphisms in THI patients, so we could not discuss our data with literature findings. In the IVIg group, "lower numbers of CD19 + B cells" in the "R131R genotype" may have some importance for explaining clinical findings, because both of these immunological factors have correlations with an increased incidence of infection.
Binstadt et al. 12 tried to speculate on how Fcγ receptor polymorphisms might influence response to IVIg therapy in some autoimmune diseases (immune thrombocytopenic purpura, systemic lupus erythematosus, multiple sclerosis, etc.) for which clinically significant Fcγ receptor polymorphisms have been described. The authors could not find any evidence that Fcγ receptor polymorphisms might impact the efficacy of IVIg therapy for these diseases. 12 Recently, two reports have documented the involvement of the FcγRIIIa polymorphism in the therapeutic response of immune thrombocytopenic purpura and non-Hodgkin's lymphoma. 13 These two studies contrast with the current study, since in addition to genotypes, allele frequencies did not show any significant difference between IVIg and non-IVIg groups. There was no clear correlation explaining the severity of THI patients with Fcγ receptor polymorphisms, so we did not search for the efficacy of IVIg therapy in different patients with different Fcγ receptor polymorphisms.
In conclusion, there is no association between the heterogeneous clinical picture of THI patients and Fcγ receptor gene polymorphisms. In other words, different genotypes or alleles of Fcγ receptor genes do not explain why some THI patients are severely symptomatic.
